Non-Psychotropic Cannabinoid2 Receptor Agonists Inhibit Breast Cancer Proliferation
Breast cancer is the second leading cause of death in women with nearly 200,000 women diagnosed each year in the U.S. Bone is the most common site for breast cancer metastases, resulting in bone loss, fractures, anemia and pain. Despite marked advances in chemotherapy treatments for early stage breast cancer, once the tumor has metastasized to the bone, few new therapies are effective in slowing disease progression and increasing survival in advanced breast cancer patients. Dr. Vanderah’s team at the University of New England is investigating the use of novel compounds that both inhibit the growth of the breast cancer cells and reduce the cancer induced bone pain and bone loss. Their studies so far suggest that these new medicines may provide breast cancer patients a superior alternative to currently available therapeutics.